YAFI Online Programming // Disease State Management and Drug Therapy

UConn Update #3

SARS-CoV-2 and COVID-19

Educational Objectives

After participating in this activity, pharmacists will be able to:

  • List developments related to treatments that are currently being investigated for COVID-19
  • Recognize changes to the CDC’s recommendations and risk criteria
  • Describe non-pharmacologic interventions to reduce the spread of SARS-CoV-19

Session Offered

Release Date: May 4, 2020

Expiration Date: December 31,2021

Course Fee

$3 for pharmacists

$3 for technicians

Session Codes

20YC44-XTX29 Pharmacist

20YC44-YKT48 Pharmacy Technician

Accreditation Hours

1.0 hours of CE


UConn faculty assembled this homestudy in response to a high demand to reliable education on coronavirus. It answers questions submitted by our learners.

Accreditation Statements

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and pharmacy technicians are eligible to participate in this application-based activity and will receive up to 0.2 CEU (2 contact hours) for completing the activity, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor on- line system and your participation will be recorded with CPE Monitor within 72 hours of submission


Grant funding: None

Cost: $3 for pharmacists $3 for technicians

Initial Release Date: May 4, 2020
Expiration Date: December 31, 2021

To obtain CPE credit, visit the UConn Online CE Center

Use your NABP E-profile ID and the session code 20YC44-XTX29 for pharmacists or 20YC44-YKT48 for pharmacy technicians to access the online quiz and evaluation.

First- time users must pre-register in the Online CE Center. Test results will be displayed immediately and your participation will be recorded with CPE Mon- itor within 72 hours of completing the requirements.

For questions concerning the online CPE activities, email joanne.nault@uconn.edu


Jeannette Y. Wick, R.Ph, MBA, FASCP, is the Assistant Director, Office of Pharmacy Professional Development, UConn School of Pharmacy, Storrs, CT.

C. Michael White, Pharm.D., FCP, FCCP; Professor and Chair, Pharmacy Practice, UConn School of Pharmacy, Storrs, CT and Director, HOPES Collaborative Group, University of Connecticut and Hartford Hospital, Hartford, CT.

Jeffrey R. Aeschlimann, Pharm.D. Is an Associate Professor, UConn School of Pharmacy, Adjunct Associate Professor, UConn School of Medicine, UConn Health, Division of Infectious Diseases.

Faculty Disclosure

All faculty have no actual or potential conflicts of interest associated with this article.

Disclosure of Discussions of Off-label and Investigational Drug Use

This activity may contain discussion of off label/unapproved use of drugs. The content and views presented in this educational program are those of the faculty and do not necessarily represent those of the University of Connecticut School of Pharmacy. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.



This is the third update to UConn’s running series on SARS-COV-2 and COVID-19. In previous continuing education (CE) activities, we discussed the virus (SARSCoV-2), the disease it causes (COVID-19), and frequently asked questions. It’s been an interesting two weeks, with change afoot daily. We appreciate your questions and interest, and have done our best to provide evidence-based information. Please feel free to share the CEs with others.


Full List of References

1. U.S. Centers for Disease Control and Prevention. Are you at higher risk for severe illness? Available at https://www.cdc.gov/coronavirus/2019-ncov/specificgroups/high-risk-complications.html. Accessed April 28, 2020.

2. U.S. Centers for Disease Control and Prevention. About Coronavirus Disease 2019 (COVID-19). Available at https://www.cdc.gov/coronavirus/2019- ncov/symptoms-testing/symptoms.html. Accessed April 27, 2020.

3. Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19. In press. Available at https://www.medrxiv.org/content/10.1101/2020.04.16.20065920v2. Accessed April 28, 2020.

4. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. In press. Available at https://www.sciencedirect.com/science/article/pii/S0924857920300996. Accessed April 28, 2020.

5. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. Available at file:///C:/Users/JEANNE~1/AppData/Local/Temp/Hydroxychloroquine%20in%20 patients%20with%20COVID-19-%20An%20openlabel,%20randomized,%20controlled%20trial%20-%20Pre-PeerRev%20-%204- 14-2020.pdf. Accessed April 28, 2020.

6. Borba MGS, Val FFA, Sampaio VS, et al; CloroCovid-19 Team. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020;3(4):e208857. doi: 10.1001/jamanetworkopen.2020.8857.

7. Guan WJ, Ni ZY, Hu Y, et al; China Medical Treatment Expert Group for Covid19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med (2020) [PMID: 32109013 DOI: 10.1056/NEJMoa2002032] [Epub ahead of print].

8. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020 Apr 10. pii: S0049-3848(20)30120-1. doi: 10.1016/j.thromres.2020.04.013. [Epub ahead of print]

9. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020 Apr;18(4):844-847. doi: 10.1111/jth.14768.

10. Arachchillage DR, Laffan M. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020 Apr 15. doi: 10.1111/jth.14820. [Epub ahead of print]

11. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 2020 Apr 9;127:104362. doi: 10.1016/j.jcv.2020.104362. [Epub ahead of print]

12. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020 Apr 27. pii: blood.2020006000. doi: 10.1182/blood.2020006000. [Epub ahead of print]

13. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020 Apr 27. pii: blood.2020006000. doi: 10.1182/blood.2020006000. [Epub ahead of print]

14. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020 Mar 25. doi: 10.1111/jth.14810. [Epub ahead of print]

15. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. April 29, 2020. Available at https://www.thelancet.com/journals/lancet/article/PIIS0140- 6736(20)31022-9/fulltext. Accessed April 30, 2020.

16. U.S. National Institute of Allergy and Infectious Diseases. NIH clinical trial shows remdesivir accelerates recovery from advanced COVID-19. April 29, 2020. Available at https://www.niaid.nih.gov/news-events/nih-clinical-trial-showsremdesivir-accelerates-recovery-advanced-covid-19. Accessed April 30, 2020.

17. Chin AWH, Chu JTS, Perera MR, et al. Stability of SARS-CoV-2 in different environmental conditions. Lancet Microbe. Available at https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(20)30003- 3/fulltext. Accessed April 28, 2020.

18. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1. N Engl J Med. In press. Available at https://www.medrxiv.org/content/10.1101/2020.03.09.20033217v1.full.pdf. Accessed April 28, 2020.

19. Talero KP, Chess B. Physical and chemical agents for microbial control. IN: Foundations in Microbiology, 9th edition. New York, NY: McGraw-Hill Education, 2015.

20. Nargi L, Braff D. What kills bactria—and what doesn’t. Reader’s Digest. Available at https://www.rd.com/advice/what-kills-bacteria/. Accessed April 28, 2020.

21. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. New Engl J Med. 2020;382(10):970- 971.

22. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. New Engl J Med. 2020;382(12):1177-1179.

23. Pan X, Chen D, Xia Y, et al. Asymptomatic cases in a family cluster with SARSCoV-2 infection. Lancet Infect Dis. 2020;20(4):410-411. doi: 10.1016/S1473- 3099(20)30114-6.

24. Bai Y, Yao L, Wei T, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020 Feb 21. doi: 10.1001/jama.2020.2565. [Epub ahead of print]

25. Kimball A HK, Arons M, et al. Asymptomatic and presymptomatic SARS-CoV2 infections in residents of a long-term care skilled nursing facility — King County, Washington, March 2020. MMWR. 2020;ePub:27March2020.

26. Wei WE LZ, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic transmission of SARS-CoV-2 — Singapore, January 23–March 16, 2020. MMWR. 2020;ePub:1April2020.

27. Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). May 1, 2020. Available at https://science.sciencemag.org/content/368/6490/489.full. Accessed May 2, 2020.

28. U.S. Centers for Disease Control and Prevention. Recommendation regarding the use of cloth face coverings, especially in areas of significant communitybased transmission. Available at https://www.cdc.gov/coronavirus/2019- ncov/prevent-getting-sick/cloth-face-cover.html. Accessed April 28, 2020.

29. [No author.] Coronavirus is growing exponentially—here’s what that really means. The Conversation. Available at https://theconversation.com/coronavirus-is-growing-exponentially-heres-whatthat-really-means-134591. Accessed April 29, 2020.

30. PR Newswire. Virginia breweries, cider makers, distilleries, beer distributors and wine makers band together to make scarce hand sanitizer. April 29, 2020. Available at https://tinyurl.com/yb7jc8hm. Accessed April 29, 2020.

31. Huffman. FDA clarifies rules on hand sanitizer. April 29, 2020. Available at https://www.consumeraffairs.com/news/fda-clarifies-rules-on-hand-sanitizer042820.html. Accessed April 30, 2020.

32. Cohen E. New York hospitals are studying a common heartburn drug as treatment for Covid-19. Available at https://www.cnn.com/2020/04/27/health/famotidine-coronavirus-northwelltrial/index.html. Accessed April 28, 2020.

33. Belli B. Yale fibrosis drug may offer new treatment path for COVID-19 lung distress. Available at https://news.yale.edu/2020/04/03/yale-fibrosis-drug-mayoffer-new-treatment-path-covid-19-lung-distress. Accessed April 28, 2020.